Abstract
Previously we reported that Apolipoprotein E (ApoE) ε4 negatively affects performance in the novel-image-novel- location (NINL) object recognition test in healthy non-demented elderly human study participants. In this study, the participants were invited to return for testing sessions 6 and 18 months after the baseline session. Using a longitudinal study design, effects of ε4 on NINL test performance were assessed in study “dropouts”, participants that did not return for the second and/or third session(s), and “finishers”, participants that returned for all sessions. There were effects of ε4 on dropout rates and NINL total scores as well as sub-scores in both dropouts and finishers. NINL total score was a predictor of ε4 participant dropout. Compared to non-ε4 dropouts, ε4 dropouts had lower NINL scores. In contrast, ε4 finishers had higher NINL scores than non-ε4 finishers. Thus, the NINL test could be a valuable tool in detecting preclinical signs of age-related cognitive impairments, particularly those associated with ε4 risk.
Keywords: ApoE, object recognition, aging, cortisol, testosterone, humans
Current Aging Science
Title: Effects of ε4 on Object Recognition in the Non-Demented Elderly
Volume: 3 Issue: 2
Author(s): Gwendolen E. Haley, Frederique Berteau-Pavy, Byung Park and Jacob Raber
Affiliation:
Keywords: ApoE, object recognition, aging, cortisol, testosterone, humans
Abstract: Previously we reported that Apolipoprotein E (ApoE) ε4 negatively affects performance in the novel-image-novel- location (NINL) object recognition test in healthy non-demented elderly human study participants. In this study, the participants were invited to return for testing sessions 6 and 18 months after the baseline session. Using a longitudinal study design, effects of ε4 on NINL test performance were assessed in study “dropouts”, participants that did not return for the second and/or third session(s), and “finishers”, participants that returned for all sessions. There were effects of ε4 on dropout rates and NINL total scores as well as sub-scores in both dropouts and finishers. NINL total score was a predictor of ε4 participant dropout. Compared to non-ε4 dropouts, ε4 dropouts had lower NINL scores. In contrast, ε4 finishers had higher NINL scores than non-ε4 finishers. Thus, the NINL test could be a valuable tool in detecting preclinical signs of age-related cognitive impairments, particularly those associated with ε4 risk.
Export Options
About this article
Cite this article as:
E. Haley Gwendolen, Berteau-Pavy Frederique, Park Byung and Raber Jacob, Effects of ε4 on Object Recognition in the Non-Demented Elderly, Current Aging Science 2010; 3 (2) . https://dx.doi.org/10.2174/1874609811003020127
DOI https://dx.doi.org/10.2174/1874609811003020127 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interaction of Buffalo Brain Cystatin with Serotonin
Current Nanoscience Histone Post-translational Modifications to Target Memory-related Diseases
Current Pharmaceutical Design Molecular Dynamics and Regulation of Butyrylcholinesterase Cholinergic Activity by RNA Binding Proteins
CNS & Neurological Disorders - Drug Targets Homocysteine Enhances Transmigration of Rat Monocytes through a Brain Capillary Endothelial Cell Monolayer via ICAM-1
Current Neurovascular Research Phosphodiesterase Inhibitors for Cognitive Enhancement
Current Pharmaceutical Design Management of Hypertension-Journey from Single Drug Therapy to Multitargeted Ligand Therapy: A Clinical Overview
Current Clinical Pharmacology COX-2 Inhibitors Celecoxib and Parecoxib: Valuable Options for Postoperative Pain Management
Current Topics in Medicinal Chemistry Huntingtons Disease: New Frontiers for Molecular and Cell Therapy
Current Drug Targets Meet Our Associate Editor
Central Nervous System Agents in Medicinal Chemistry Usefulness of CSF Biomarkers in Predicting the Progression of Amnesic and Nonamnesic Mild Cognitive Impairment to Alzheimer’s Disease
Current Aging Science Progress and Promise of Nur77-based Therapeutics for Central Nervous System Disorders
Current Neuropharmacology Vanutide Cridificar and the QS-21 Adjuvant in Japanese Subjects with Mild to Moderate Alzheimer’ s Disease: Results from Two Phase 2 Studies
Current Alzheimer Research Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer's Disease
Current Alzheimer Research Histamine H3 Receptor (H3R) Antagonists and Inverse Agonists in the Treatment of Sleep Disorders
Current Pharmaceutical Design Antiplatelet Therapies: Aspirin at the Heart of New Directions
Cardiovascular & Hematological Disorders-Drug Targets When is a Proof-of-Concept (POC) not a POC? Pomaglumetad (LY2140023) as a Case Study for Antipsychotic Efficacy
Current Pharmaceutical Design Vitamins Mediate Immunological Homeostasis and Diseases at the Surface of the Body
Endocrine, Metabolic & Immune Disorders - Drug Targets Mitochondria: A Target for Neuroprotective Interventions in Cerebral Ischemia-Reperfusion
Current Pharmaceutical Design The Role of microRNA in Ischemic and Hemorrhagic Stroke
Current Drug Delivery